Company research
CNS Pharmaceuticals, Inc.
CIK 1729427Updated Sep 27, 2026
SecurityCNSP · NASDAQ · equity
CNSP price & chart
Loading TradingView…
NASDAQ:CNSP on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
DEFA14A filing
DEF 14A filing
SCHEDULE 13G/A filing
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,623,466Source | 8,700,943Source | 1,700,853Source | 13,053,115Source |
| Property, Plant and Equipment, NetUSD | 17,703Source | 6,005Source | 4,933Source | 5,664Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,201,014Source | 6,461,378Source | 548,721Source | 10,055,407Source |
| Assets, CurrentUSD | 8,102,801Source | 8,658,508Source | 1,591,170Source | 12,564,645Source |
| Prepaid Expense and Other Assets, CurrentUSD | 856,301Source | 1,293,954Source | 839,590Source | 2,509,238Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,100,910Source | 2,524,332Source | 6,132,968Source | 4,920,259Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 633Source | 1,414Source | 6,214Source | 1,617Source |
| Additional Paid in CapitalUSD | 104,797,191Source | 90,599,901Source | 65,128,574Source | 58,846,916Source |
| Retained Earnings (Accumulated Deficit)USD | -100,275,268Source | -84,424,704Source | -69,566,903Source | -50,715,677Source |
| Stockholders' Equity Attributable to ParentUSD | 4,522,556Source | 6,176,611Source | -4,432,115Source | 8,132,856Source |
| Liabilities and EquityUSD | 8,623,466Source | 8,700,943Source | 1,700,853Source | 13,053,115Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,100,910Source | 2,524,332Source | 6,132,968Source | 4,920,259Source |
| Accounts Payable, CurrentUSD | — | — | — | 3,681,900Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 828,391Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 187,728Source | 838,957Source | 1,007,417Source | 1,202,966Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | 1,700,455Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,811,107Source | -17,113,299Source | -14,140,031Source | -10,557,815Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -18,175Source | -4,188Source | -3,901Source | -4,422Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 18,175Source | 4,188Source | 3,901Source | 4,422Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,568,918Source | 23,030,144Source | 4,637,246Source | 15,613,127Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,201,014Source | 6,461,378Source | 548,721Source | 10,055,407Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,267Source | 13,599Source | 13,805Source | 8,094Source |
| Additional Financial Items | ||||
| Amortization of Deferred ChargesUSD | — | — | 0Source | 334,138Source |
| DepreciationUSD | 3,918Source | 3,306Source | 4,134Source | 11,756Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -2,559Source | 190Source | -498Source | -3,111Source |
| General and Administrative ExpenseUSD | 6,214,619Source | 5,611,800Source | 4,769,502Source | 5,967,052Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 15,230Source | 16,120Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -15,850,564Source | -14,857,801Source | -18,851,226Source | -15,274,134Source |
| Nonoperating Income (Expense)USD | 135,995Source | 44,142Source | 13,882Source | -7,027Source |
| Operating ExpensesUSD | 15,986,559Source | 14,901,943Source | 18,865,108Source | 15,267,107Source |
| Proceeds from Issuance of Common StockUSD | 14,046,430Source | 23,376,375Source | 2,317,599Source | 16,038,093Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -15,986,559Source | -14,901,943Source | -18,865,108Source | -15,267,107Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -15,850,564Source | -14,857,801Source | -18,851,226Source | -15,274,134Source |
| Earnings Per Share, BasicUSD per share | -35.75Source | -38.87Source | -5Source | -11.22Source |
| Earnings Per Share, DilutedUSD per share | -35.75Source | -38.87Source | -5Source | -11.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 443,369Source | 382,241Source | 3,767,372Source | 1,361,737Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 443,369Source | 382,241Source | 3,767,372Source | 1,361,737Source |
| Interest Expense (non-operating)USD | 15,230Source | 16,120Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 6,214,619Source | 5,611,800Source | 4,769,502Source | 5,967,052Source |
| Interest ExpenseUSD | — | — | 13,805Source | 7,027Source |
| Interest Income, OperatingUSD | — | — | 27,687Source | — |
| Labor and Related ExpenseUSD | — | — | — | 76,087Source |
| Nonoperating Income (Expense)USD | 135,995Source | 44,142Source | 13,882Source | -7,027Source |
| Operating ExpensesUSD | 15,986,559Source | 14,901,943Source | 18,865,108Source | 15,267,107Source |
| Research and Development ExpenseUSD | 9,771,940Source | 9,290,143Source | 14,095,606Source | 9,300,055Source |